Vyleesi and Apixaban Interaction: What You Need to Know

How Bremelanotide Affects Oral Drug Absorption

Bremelanotide activates melanocortin-4 receptors (MC4R) in the central nervous system, a mechanism that triggers nausea and slows gastrointestinal motility in a dose-dependent fashion. That slowed gastric emptying is the primary pharmacokinetic concern when combining Vyleesi with any oral medication, apixaban included.

The FDA-approved prescribing information for bremelanotide states that coadministration with oral naltrexone reduced naltrexone Cmax by approximately 44% and delayed its Tmax by roughly 30 minutes [1]. The area under the curve (AUC) also decreased, though to a lesser degree. Because bremelanotide is given subcutaneously and naltrexone is taken orally, the FDA label attributes the change to delayed gastric emptying rather than to metabolic enzyme competition. The label explicitly warns prescribers to have patients take oral medications at least one hour before injecting bremelanotide.

Apixaban reaches peak plasma concentration within 3 to 4 hours of an oral dose under normal conditions, according to the Eliquis prescribing information [2]. A delay in gastric emptying could shift that Tmax later and blunt the Cmax. For a drug with a relatively narrow therapeutic window that prevents both clotting and bleeding, any change in the absorption profile deserves clinical attention. The practical fix is straightforward: take apixaban first, wait at least 60 minutes, then inject Vyleesi.

CYP3A4 and P-Glycoprotein: Evaluating the Metabolic Overlap

Apixaban depends on CYP3A4 for roughly 25% of its hepatic metabolism and is also a substrate of the efflux transporter P-glycoprotein (P-gp). Strong dual inhibitors of CYP3A4 and P-gp (ketoconazole, ritonavir) can double apixaban exposure, which is why the apixaban label recommends a 50% dose reduction when such inhibitors are coadministered [2].

Bremelanotide does not fit that risk profile. In vitro studies submitted in the bremelanotide New Drug Application showed no meaningful inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations well above therapeutic plasma levels [1]. The drug also did not induce CYP3A4 mRNA expression in cultured human hepatocytes. No published data identify bremelanotide as a P-gp inhibitor or inducer.

That means the two main pathways through which other drugs raise apixaban levels (CYP3A4 inhibition and P-gp blockade) are not triggered by bremelanotide at its 1.75 mg subcutaneous dose. A 2020 review of melanocortin receptor agonist pharmacology published in the Journal of Clinical Pharmacology confirmed minimal CYP-mediated interaction liability for bremelanotide across tested isoforms [3].

This distinction matters. The interaction between bremelanotide and apixaban is absorptive, not metabolic. Prescribers do not need to reduce the apixaban dose solely because a patient uses Vyleesi.

Blood Pressure and Cardiovascular Considerations

Bremelanotide raises blood pressure transiently. The pooled RECONNECT phase 3 program (two identically designed trials, N = 1,247 combined) documented a mean systolic increase of approximately 2.5 mmHg and a diastolic increase of roughly 3.0 mmHg, peaking about 2 to 3 hours after injection and resolving within 12 hours in most subjects, as reported in a 2019 publication in Obstetrics & Gynecology [4].

For patients on apixaban, the concern is indirect but real. Uncontrolled hypertension is an independent risk factor for both ischemic stroke and intracranial hemorrhage. The 2019 American Heart Association / American Stroke Association guidelines list blood pressure management as a modifiable variable in patients receiving anticoagulation [5]. A transient 2 to 3 mmHg bump is small in isolation, but if the patient already runs at the upper boundary of acceptable pressure, even modest spikes add incremental risk during anticoagulant therapy.

The bremelanotide label contraindicates the drug in patients with uncontrolled hypertension or known cardiovascular disease [1]. If a patient on apixaban has well-controlled blood pressure and no history of stroke or transient ischemic attack, the transient hemodynamic effect of bremelanotide is unlikely to change her anticoagulation risk category. If her blood pressure is borderline or labile, the combination warrants closer monitoring or may not be appropriate.

What the FDA Label Says About Coadministration

The bremelanotide prescribing information addresses oral drug interactions in Section 7 [1]. Three points are directly applicable.

First, the label recommends taking oral medications at least one hour prior to bremelanotide injection to avoid absorption interference. This timing buffer allows an oral drug to clear the stomach before bremelanotide slows gastric motility.

Second, the label specifically names naltrexone and indomethacin as drugs studied in formal pharmacokinetic interaction trials. Naltrexone Cmax dropped 44%. Indomethacin Cmax dropped approximately 36%. AUC reductions were smaller but still present [1]. No formal interaction study with apixaban has been published, so clinicians must extrapolate from these data.

Third, the label restricts use in women with cardiovascular risk factors, which has implications for the typical apixaban patient. Apixaban is most commonly prescribed for atrial fibrillation or venous thromboembolism, conditions that carry their own cardiovascular burden. A prescriber evaluating the combination should assess overall cardiovascular status, not just the drug-drug interaction in isolation.

Monitoring Recommendations for Patients on Both Drugs

Patients using both bremelanotide and apixaban should follow a structured monitoring plan that covers absorption, hemodynamics, and anticoagulation status.

Timing protocol. Take apixaban at its regularly scheduled time. Wait at least 60 minutes. Then inject bremelanotide if needed that day. This order preserves apixaban absorption kinetics and aligns with the FDA label guidance [1].

Blood pressure checks. Measure blood pressure before injecting bremelanotide and again 2 to 3 hours post-injection during the first several uses. If the post-injection reading exceeds 140/90 mmHg or rises more than 10 mmHg above baseline, contact the prescribing clinician before using bremelanotide again.

Signs of altered anticoagulation. Watch for unusual bruising, prolonged bleeding from minor cuts, blood in urine or stool, or heavy menstrual bleeding. While bremelanotide does not directly affect coagulation, any disruption in apixaban absorption could theoretically reduce anticoagulant efficacy (raising clot risk) or, less likely, alter the time course of drug exposure in unpredictable ways.

Anti-Xa level testing. Routine anti-factor Xa monitoring is not standard practice for apixaban, but the American Society of Hematology 2020 VTE guidelines note that drug-specific anti-Xa assays may be useful when absorption or adherence is in question [6]. If a prescriber has concerns that bremelanotide is meaningfully reducing apixaban bioavailability, a trough anti-Xa level drawn 12 hours post-dose can confirm whether apixaban exposure remains therapeutic.

Frequency limits. Do not exceed one bremelanotide injection per 24 hours or eight injections per calendar month [1]. Each injection is an independent absorption-disrupting event, so spacing injections limits cumulative impact on apixaban pharmacokinetics.

Clinical Severity Rating and DDI Database Classification

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not currently assign a high-severity flag to the bremelanotide-apixaban pair. The interaction is classified as moderate or low by most systems, primarily because it rests on the gastric-emptying mechanism rather than on direct enzyme inhibition or pharmacodynamic antagonism.

For comparison, the apixaban-ketoconazole interaction carries a "major" or "contraindicated" flag in most databases because ketoconazole doubles apixaban AUC through strong CYP3A4 and P-gp inhibition [2]. The apixaban-rifampin interaction is similarly flagged because rifampin halves apixaban exposure through CYP3A4 and P-gp induction, as demonstrated in a crossover study published in the British Journal of Clinical Pharmacology [7].

Bremelanotide does neither of those things. It slows absorption, which shifts timing but does not necessarily reduce total drug exposure (AUC) by the same magnitude. The naltrexone interaction data showed a 44% Cmax reduction but a smaller AUC reduction, consistent with delayed rather than diminished absorption [1].

The clinical takeaway: this is not a combination that requires automatic dose adjustment or avoidance. It requires timing discipline and awareness.

Who Should Avoid the Combination

Some patient profiles make concurrent use inadvisable regardless of timing adjustments.

Patients with uncontrolled hypertension should not receive bremelanotide at all, per the label contraindication [1]. If a woman on apixaban has blood pressure consistently above 140/90 mmHg despite treatment, bremelanotide is off the table independent of any interaction concern.

Patients with a history of stroke or systemic embolism while on apixaban warrant caution. These patients are already at the higher end of thromboembolic risk. Introducing a variable that could delay anticoagulant absorption, even transiently, adds unnecessary uncertainty.

Patients concurrently taking strong CYP3A4 inhibitors (such as ketoconazole or HIV protease inhibitors) alongside apixaban are already on a reduced apixaban dose. Adding bremelanotide introduces a third variable into an already complex pharmacokinetic picture. In these cases, a pharmacist-led drug interaction review is appropriate before prescribing.

Patients with gastroparesis or other motility disorders. Bremelanotide further slows an already sluggish GI tract, magnifying the absorption delay for all oral medications, not only apixaban.

Practical Counseling Points for Patients

A patient receiving both prescriptions needs clear, specific instructions. The Endocrine Society's 2020 clinical practice guideline on female sexual dysfunction emphasizes the importance of patient education when prescribing bremelanotide, given the drug's unique on-demand dosing pattern and side-effect profile [8].

Tell the patient: take your apixaban tablet with water at your normal time. Set a timer for 60 minutes. Only after that hour has passed should you inject bremelanotide. Do not use bremelanotide more than once in 24 hours. If you vomit within 30 minutes of taking apixaban (bremelanotide causes nausea in roughly 40% of users per the RECONNECT trials [4]), contact your prescriber, because the apixaban dose may not have been absorbed.

Nausea management itself matters. The RECONNECT trials reported nausea in 40.0% of bremelanotide-treated patients versus 1.3% on placebo [4]. If nausea leads to vomiting shortly after an apixaban dose, the patient may lose that dose entirely, creating a gap in anticoagulation coverage. Prescribers may consider ondansetron pretreatment for patients who experience recurrent post-injection nausea, though this adds another drug to the regimen and its own interaction profile should be reviewed.

One final point: bremelanotide is injected subcutaneously, not taken orally. It bypasses the GI tract entirely for its own absorption. The interaction is one-directional. Apixaban does not affect bremelanotide levels.